GlassScriptPhysician profile
Brooklyn Crisler
NPI 1205469517
$2,279.86
in general payments reported to CMS, 2019-2025
31 companies · $63.65 in 2025
The $63.65 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $169 · 2022: $336 · 2023: $809 · 2024: $902 · 2025: $63.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.77 | 2022-2025 | |
| Corium, LLC | $372.05 | 2023-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.90 | 2021-2023 | Xifaxan, Trulance |
| Boston Scientific Corporation | $133.93 | 2024 | Wavewriter Alpha Prime 16 |
| Qol Medical, LLC | $130.54 | 2022-2023 | Sucraid |
| Novo Nordisk INC | $110.40 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $95.50 | 2022-2023 | Entyvio |
| Lilly USA, LLC | $91.80 | 2023-2024 | Mounjaro, Zepbound |
| Ironshore Pharmaceuticals INC. | $91.27 | 2023-2024 | Jornay Pm |
| Pfizer INC. | $67.71 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $65.03 | 2024 | Farxiga, Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $57.73 | 2024 | |
| Ironwood Pharmaceuticals, INC | $51.61 | 2022-2024 | |
| Janssen Biotech, INC. | $39.24 | 2023 | Stelara |
| Ardelyx, INC. | $37.80 | 2023 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $33.65 | 2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $31.03 | 2024 | Capvaxive, Vaxneuvance, Gardasil |
| Nestle Healthcare Nutrition INC. | $25.84 | 2022-2023 | |
| Daiichi Sankyo INC. | $24.02 | 2023 | Injectafer |
| Collegium Pharmaceutical, INC. | $23.81 | 2021 | |
| Genzyme Corporation | $22.81 | 2023 | |
| Supernus Pharmaceuticals, INC. | $22.24 | 2023 | Qelbree |
| Celgene Corporation | $19.61 | 2022 | |
| Inspire Medical Systems, INC. | $19.43 | 2024 | Inspire |
| Exact Sciences Corporation | $17.62 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $16.28 | 2024 | Veozah |
| Neos Therapeutics, LP | $15.31 | 2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $13.67 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.37 | 2021 | |
| Almatica Pharma LLC | $13.22 | 2021 | |
| Pacira Therapeutics, INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooklyn Crisler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.